High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
about
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsType 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightNon-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.Serum resistin positively correlates with serum lipids, but not with insulin resistance, in first-degree relatives of type-2 diabetes patients: an observational study in China.Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis.Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 DiabetesCharacterisation of liver fat in the UK Biobank cohort.Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population.Risk Factors for Hypogonadism in Male Patients with Type 2 DiabetesGlobal Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority PopulationsNon-alcoholic fatty liver disease and diabetes.Plasma glucose and insulin response to two oral nutrition supplements in adults with type 2 diabetes mellitus.Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.Metreleptin Treatment in Three Patients with Generalized Lipodystrophy.Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Therapeutic application of GPR119 ligands in metabolic disorders.The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.Diagnosis of non-alcoholic fatty liver disease (NAFLD).NAFLD and diabetes mellitus.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.Non-alcoholic fatty liver disease-a chronic disease of the 21(st) century.Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD).Serum metabolomic profiling highlights pathways associated with liver fat content in a general population sample.Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection.Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.Clinical relevance of liver histopathology and different histological classifications of NASH in adults.NAFLD/NASH in patients with type 2 diabetes and related treatment options.Nicotine Metabolism in Adults with Type 2 Diabetes.Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes.Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.
P2860
Q26744631-C3050485-2B8A-4657-9867-C5240B3C382BQ26751258-9EFEAA1C-6C62-40A6-AFCE-85662E44EA47Q26752583-C0E33D49-2DB3-4A5B-9F04-0EA6C3BE805EQ30366569-18337DB5-0AA7-4EA7-9E5F-A4654E450F14Q33606147-7D8C407F-51B3-4974-992E-1ED3CEB1C738Q33627245-45118FCA-0EEE-4F66-AB6A-A6ED9C32830DQ33802278-6167BB39-7CD5-4433-A454-03565D48027FQ33805278-6E1F8C2C-ECC6-4597-AD6B-C0FDB62061C0Q35740071-4DCDBBAE-275E-4548-9E9D-75CAAE17E825Q36291704-1BA14343-8346-43A8-81C6-1DEFBA4466ADQ36649345-DE6D57D8-9C45-4964-93FC-57BB2ADFDE6CQ36661316-6C550F00-967D-49A9-ACCD-DCA47BF893E1Q36818424-189E6FF8-0BAC-4F42-870A-8C7AA64862BAQ37091659-21FD6FAB-3C56-4390-ADB5-32A944151C89Q37236488-0F904C78-1339-4B74-BE68-FFC43119D01FQ37261712-A0A05D22-3FE6-4D48-AFA4-B24AB1D48609Q37567810-53A988BA-13B7-43AA-B599-C87D33805109Q38287516-FD2B01AA-EF3B-473D-A49A-57B599F438CEQ38627907-708864D2-E469-40D2-8EA3-A98BC1A6058DQ38655382-12DCD867-2BD2-4DBE-945D-DD88319506AAQ38676257-D6FF98F9-F996-467C-ABAF-4AB3C250ECF6Q38811383-98B58F81-8753-455F-A3FE-AC7BB6A596D6Q38978347-0D37F25A-D633-46F7-BDE9-54F8474FDE47Q39170225-851BB70A-FA14-4CB9-AE21-DE30B77CE042Q39306199-1825EC75-D885-41F1-B671-FC009DCBE396Q39333577-3CFF6CFD-4C84-4A7E-9E1E-506AE76B43E8Q39519124-0518AD16-2903-4019-9983-137BE1637A78Q40257413-2B7C7BD0-A39B-4789-9F37-A1F517619A74Q40551135-AE70F0AB-FAC3-42D8-A225-173F2101B321Q41050215-4BD8180C-4C95-4BC9-BF78-A8F0C85559F2Q42283321-2CD66939-FA31-463A-B705-C673D42354FBQ47136445-CD39A0EA-68B6-4C9C-AA0B-4E2D3893927EQ47436758-44C9AAC9-5D49-4BD9-B04B-2230FB4BFCC7Q47581786-0B8B49B0-68CC-4929-B494-B7F140B3BF90Q47592767-4448695D-57D3-4E69-914B-A57766752ED0Q47741943-6AF4388D-5064-4014-AF48-BD69DD114836Q47859313-4BFACCB0-D520-4D2D-8160-D16402C019C2Q48062300-5433B82A-FD5D-47B3-AB63-CD2DFC3E04EEQ48144953-88FD8358-2488-4BAC-82CA-8097958CBA09Q49501260-71613DB6-A5FE-487E-ADD5-96F144D5C5E1
P2860
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
High Prevalence of Nonalcoholi ...... lasma Aminotransferase Levels.
@en
High Prevalence of Nonalcoholi ...... lasma Aminotransferase Levels.
@nl
type
label
High Prevalence of Nonalcoholi ...... lasma Aminotransferase Levels.
@en
High Prevalence of Nonalcoholi ...... lasma Aminotransferase Levels.
@nl
prefLabel
High Prevalence of Nonalcoholi ...... lasma Aminotransferase Levels.
@en
High Prevalence of Nonalcoholi ...... lasma Aminotransferase Levels.
@nl
P2093
P356
P1476
High Prevalence of Nonalcoholi ...... Plasma Aminotransferase Levels
@en
P2093
Beverly Orsak
Diane Biernacki
Joan Hecht
Kenneth Cusi
Maryann Maximos
Paola Portillo-Sanchez
Romina Lomonaco
Sreevidya Subbarayan
P304
P356
10.1210/JC.2015-1966
P407
P577
2015-04-17T00:00:00Z